Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07548099 · ClinicalTrials.gov registry record
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
A clinical trial, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07548099: Recruiting study, sponsored by University of Pennsylvania.
NCT07548099 is a clinical trial that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07548099 is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography). The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.
Primary Outcome
• Measure uptake of 64Cu-DOTA-ECL1i in patients with abdominal aortic aneurysm at two time points to evaluate intra-individual variability of radiotracer uptake
Interventions
- DRUG 64Cu-DOTA-ECL1i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2029-04-30 |
What NCT07548099 shows while recruiting
NCT07548099 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 64Cu-DOTA-ECL1i is the first listed.
NCT07548099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07548099 about?
NCT07548099 is a clinical study titled "Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)". This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography). The aim is to collect data using a new...
What is the current status of trial NCT07548099?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-04-30. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT07548099?
The interventions under investigation include: 64Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT07548099?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI